Cambridge Cognition Share Discussion Threads

[cheshire man] 05/6/2014 17:57

ShareSoc Company Seminar Announcement



The line-up for our next seminar at which public companies will be presenting on the 25th June is now complete and is given below. This event is in the City of London, with registration starting at 4.00 pm. Four companies will be presenting this month and answering your questions, which are:



- Cambridge Cognition (COG): Cognitive assessment software for use in clinical trials, research and healthcare provision.

[cheshire man] 05/6/2014 10:23

Finncap retains £1 tp "with comfort" :-)


Major Cantab Solutions contract CORP
A £1.6m contract to provide cognitive safety assessment on a Phase III trial
of a cardiovascular drug has been signed. Whilst we are making no
changes to our forecasts, this major contract provides confidence in our
full-year estimates.
􀀗Contract details. The contract, totalling £1.6m, is to provide cognitive testing
support for a global multi-year Phase III study of a cardiovascular drug being
developed by an unnamed major biopharmaceutical company. The cognitive
testing is to evaluate the CNS safety of the drug.
􀀗Implications. Increasingly, there is a regulatory requirement to assess
cognitive side effects of drugs, even if they are not indicated for a CNS
condition, and this contract illustrates that Cambridge Cognition's battery of
cognitive function tests can be deployed in such a way in a highly regulated
environment. Cambridge Cognition anticipates that £0.8m of revenue will be
recognised in the current financial year. Whilst we make no changes to our
forecasts, this contract provides us with comfort in our £2.8m revenue forecast
for Cantab Solutions this year.

[cheshire man] 05/6/2014 07:55

Nice news for us this morning :-)

[battlebus2] 05/6/2014 07:33

Morning janeann, given turnover last year was 4 million this is a sizeable contract win. Worth a small punt under 70p imv.

[janeann] 05/6/2014 07:27

That does look positive battlebus. I hadn't considered that angle for COGs tests; I was less positive on the early dementia screening as I am not certain how the results might be used, but will look a little more closely at this company now.

[sharesoc] 30/5/2014 11:52

Shareholders and potential investors in Cambridge Cognition will probably be interested in attending ShareSoc's growth company seminar where COG will be presenting. More at: hxxp://www.sharesoc.org/seminarjune2014.html

[cheshire man] 28/5/2014 08:47

Beat me to it bb:-)

[battlebus2] 28/5/2014 07:12

More good news this morning....

Cantab Mobile rolled out in North East Lincolnshire CCG

Cambridge Cognition Holdings plc, (AIM: COG), which specialises in computerised neuropsychological tests including those enabling the early detection of dementia, announces that North East Lincolnshire Clinical Commissioning Group ('CCG') has recently introduced the Cantab Mobile app in five GP surgeries, five pharmacies and Grimsby hospital to help diagnose dementia earlier.

North East Lincolnshire is the latest CCG to roll out Cantab Mobile into GP surgeries, pharmacies and hospitals making the total number of CCGs rolled out in the UK 28. This technology has been introduced as part of a three-month evaluation. Cantab Mobile is the leading medical software for primary care allowing doctors to detect the earliest signs of clinically relevant memory problems by asking the patients to remember and match different shapes and patterns that appear on the iPad.

In April 2013 the Company announced the specifications from the NHS Commissioning Board for the four new directed enhanced services ('DES') that were to be offered to GP practices in 2013/14. For dementia this has now been extended into 2014/15. The specification prioritises, amongst other conditions, the timely diagnosis and support for people with dementia. This means that by rolling out Cantab Mobile the GP surgeries can expect to receive financial incentives to test anyone in the community, encouraging earlier diagnosis in the community.

Commenting, Nick Kerton, Chief Executive Officer of Cambridge Cognition, said: "Dementia currently costs the UK over £2.3 billion a year and if we are going to reduce this figure, early diagnosis is key. We are therefore extremely pleased that North East Lincolnshire has adopted Cantab Mobile to improve diagnosis rates in the area."

[battlebus2] 24/5/2014 12:32

Featured in Shares magazine this week. Positive article and states we should produce a maiden profit next year.

[battlebus2] 14/5/2014 09:05

Sharesoc growth company event has COG attending, the new date is 25th June.

[battlebus2] 08/5/2014 07:07

Fairly upbeat...AGM Statement

Cambridge Cognition Holdings plc, (AIM: COG), which specialises in computerised neuropsychological tests including those enabling the early detection of dementia, will hold its Annual General Meeting today at 10.00am at the offices of finnCap, 60 New Broad Street, London, EC2M 1JJ.

At the meeting Nick Kerton, Chief Executive Officer, will provide shareholders with the following update:

As I outlined in our Preliminary Results statement the business now has a clear strategic focus and we have in place a commercial infrastructure which will allow us to convert our wealth of scientific know-how into sustainable and growing commercial sales.

We have had a positive start to trading in the first quarter of the new financial year and remain confident that we will return the business to growth in 2014.

[sharesoc] 07/4/2014 10:13

Reminder that shareholders and potential investors in Cambridge Cognition will probably be interested in attending this event on the Sharesoc website: www.sharesoc.org/seminarmay2014.html

[battlebus2] 02/4/2014 07:10

Directorate Change

Cambridge Cognition Holdings plc, (AIM: COG), which specialises in computerised neuropsychological tests including those enabling the early detection of dementia, announces the appointment of Michael Lewis as Non-Executive Chairman. Michael joined the Board of Cambridge Cognition in 2013 as a Non-Executive Director and has gained over 25 years' experience in the global health and pharma industry.

Dr Jane Worlock, currently Non-Executive Chairman of the Company, has given notice to the Company of her intention to resign and will step down from the conclusion of the Company's forthcoming AGM, at which point Michael Lewis' appointment will take effect.

[battlebus2] 01/4/2014 23:01

Good to see them presenting and helping raise their profile to potential investors.

[sharesoc] 01/4/2014 22:34

Shareholders and potential investors in Cambridge Cognition will probably be interested in attending this event under the events tab at the Sharesoc website: www.sharesoc.org/seminarmay2014.html

[battlebus2] 16/3/2014 11:50

An interview with Andrew Blackwell from January 2013.

hxxp://www.news-medical.net/news/20130108/Dementia-diagnosis-an-interview-with-Dr-Andrew-Blackwell-Chief-Scientific-Officer-Cambridge-Cognition.aspx

[battlebus2] 14/3/2014 15:54

Ticking up again :))

[battlebus2] 14/3/2014 07:05

Nesta report features Cambridge Cognition

Cambridge Cognition Holdings plc, (AIM: COG), which specialises in computerised neuropsychological tests including those enabling the early detection of dementia, welcomes the publication of The Nesta report where the Company features heavily, in regards to the new wave of medtech companies leading the UK's Silicon Valley revolution.

Nesta is the UK's innovation foundation, an independent charity, helping people and organisations bring ideas to life. In this report, Silicon Valley Comes to the UK (SVC2UK) and Nesta present an overview of innovative companies and how they will play into changes in the broader healthcare sector.

Cambridge Cognition is listed as one of the companies that manages the complex relationships between doctors, researchers and government policy. The Company also features due to the technology being used in several hundred clinical research sites in over 50 countries, testing patients' cognitive function to enable faster diagnosis, as well as being used in clinical trials. Connectivity has enabled real-time data streaming and visualisation allowing the Company technology to check patient responses against expectations, measure, monitor and recommended procedural modifications (e.g. to accelerate patient enrolment) for research and clinical institutions even as the trial is progressing - reducing costs and improving data quality. Cambridge Cognition's research team use this information to test the underlying software, providing phased update of reference standards for assessing patients.

For the full report please visit:
hxxp://www.nesta.org.uk/sites/default/files/refilling_the_innovators_prescription.pdf

[ukinvestor220] 13/3/2014 21:10

continuing to watch

[battlebus2] 13/3/2014 18:55

Cambridge Cognition Holdings PLC expressed confidence Thursday that it would return to growth in 2014, after it posted a widened pretax loss in 2013 due to lower revenue.


Cambridge Cognition provides computerised neuropsychological tests, particularly to enable early detection of dementia. It floated on AIM in April 2013.

The company posted a pretax loss of GBP3.0 million in 2013, widened from GBP1.6 million in the previous year, as revenue declined to GBP4.2 million from GBP5.7 million.

Revenue was hampered by a weaker performance from the company's clinical trials business, where sales of its Cantab Solutions declined to GBP2.5 million from GBP4.2 million. Cambridge Cognition said there were fewer new studies using cognitive assessments in 2013, and the timing of expected orders from pharmaceutical clients has shifted later.

Revenues in the company's academic business rose to GBP1.5 million from GBP1.4 million, and revenues from its newly launched iPad-based product Cantab Mobile rose to GBP158,000 from GBP98,000.

Cambridge said that 415 Cantab Mobile trial licenses are in use across the UK, and noted that it had seen an excellent trial conversion rate so far. The company raised GBP5.0 million in its initial public offering, which it planned to use to accelerate the roll out of the mobile product.

The company said it had seen a positive start to trading in the first quarter of 2014. Although its clinical trials business has seen a slow start, it has sped up as it signed contracts for new studies. Cambridge said it remains on track to deliver growth in this business in 2014.

Cambridge plans to launch three new products in the third quarter for both clinical and academic applications.

"We have worked hard to refocus the business on commercial success, and I am confident that we will return the business to growth in 2014," said Chief Executive Nick Kerton in a statement.



hxxp://www.businessweekly.co.uk/biomedtech-/16655-cambridge-cognition-shares-fall-on-bigger-loss

[battlebus2] 13/3/2014 08:07

Market reaction not good but i'm still of the belief these will be much higher after the 2014 results but as ever dyor etc.

[battlebus2] 13/3/2014 07:24

Outlook

Cambridge Cognition now has a clear strategic focus and we have in place a commercial infrastructure which will allow us to convert our wealth of scientific know-how into sustainable and growing commercial sales. We are better positioned to deliver significant revenue growth in the future as a product focused business with effective routes to market in the UK as well as other international territories. We look forward to 2014 trading with optimism.

We have been very pleased with the positive start to trading in the first quarter of the new financial year. We have seen a number of NHS procurement submissions for Cantab Mobile early in the year which we expect to see convert into sales presently. Outside of the UK we are encouraged by the first assessment of Cantab Mobile in the US and we recorded our first sale into Sweden for this product. Whilst the first quarter was a slow start for our clinical trials business we have seen a subsequent acceleration of sales and have recently signed contracts relating to six new studies and so we remain on target to deliver growth in this market in 2014. We also expect to see the benefits of our newly appointed Business Development Director for Europe, who alongside our new US VP Business Development will work to drive our clinical trials sales.

We are on target to launch three new products in Q3 for both clinical and academic applications. We have successfully completed the first stage of beta testing for these products which will provide the basis of a new platform for future product development.

[battlebus2] 13/3/2014 07:19

Results out Cheshire Man which don't look that good given the loss in eps etc though they did make a gross profit of 3.66 million on an increased profit margin of 88.2% but as i said before it's the outlook for 2014 that matters here and we are seeing an increase in sales.

We still have an excellent trial conversion rate, however given the timing of the full commercial launch last year many of the CCGs we are working with have already fixed annual spending budgets. Despite this, interest for the product remains strong and we expect to benefit from the allocation of 2014 budgets. We are currently engaged in active discussions with 126 of the 211 CCGs in the UK. The new financial year has already seen an uplift in Cantab Mobile sales and we expect to benefit from much greater awareness of Cantab Mobile across CCGs.